Delayed Hypoxemia Following Traumatic Brain Injury Exacerbates White Matter Injury. Issue 8 (August 2016)

• Record Type: Journal Article
• Authors: Parikh, Umang; Williams, Melissa; Jacobs, Addison; Pineda, Jose A.; Brody, David L.; Friess, Stuart H.
• Is Part Of: Journal of neuropathology and experimental neurology. Volume 75:Issue 8(2016)
• Publication Date: 2016-08
• Subjects: Axonal injury -- Brain hypoxia -- Controlled cortical impact -- Delayed hypoxemia -- Secondary injury -- Traumatic brain injury; Neurology -- Diseases -- Periodicals; Neurology -- Diseases -- Physiopathology -- Periodicals; 616.8047
• DOI: 10.1093/jnen/nlw045
• Languages: English
• ISSNs: 0022-3069

Abstract

Abstract : Hypoxemia immediately following traumatic brain injury (TBI) has been observed to exacerbate injury. However, it remains unclear whether delayed hypoxemia beyond the immediate postinjury period influences white matter injury. In a retrospective clinical cohort of children aged 4–16 years admitted with severe TBI, 28/74 (35%) patients were found to experience delayed normocarbic hypoxemia within 7 days of admission. Based on these clinical findings, we developed a clinically relevant mouse model of TBI with delayed hypoxemia by exposing 5-week old (adolescent) mice to hypoxic conditions for 30 minutes starting 24 hours after moderate controlled cortical impact (CCI). Injured mice with hypoxemia had increased axonal injury using both β-amyloid precursor protein and NF200 immunostaining in peri-contusional white matter compared with CCI alone. Furthermore, we detected increased peri-contusional white matter tissue hypoxia with pimonidazole and augmented astrogliosis with anti-glial fibrillary acidic protein staining in CCI + delayed hypoxemia compared with CCI alone or sham surgery + delayed hypoxemia. Microglial activation as evidenced by Iba1 staining was not significantly altered by delayed hypoxemia. These clinical and experimental data indicate the prevention or amelioration of delayed hypoxemia effects following TBI may provide a unique opportunity for the development of therapeutic interventions to reduce axonal injury and improve clinical outcomes.